64．溴隐亭
出处：按学科分类—医药、卫生 军事医学科学出版社《临床常用进口药物手册》第366页（24022字）
【中文释文】：
多巴胺受体激动剂、促乳素分泌抑制剂
〔成分〕
每片溴隐亭(中央有割线)含Bromocriptini*mesilati2．5mg，胶囊制剂含有5mg及10mg2种。
*国际非专利药名记载：为2-溴-α-麦角环肽。
溴隐亭的应用范围可分为：内分泌病学适应证，神经病学适应证。
一、内分泌病学适应证
〔特点和作用〕
溴隐亭抑制垂体前叶激素促乳素的分泌，而不影响其它正常水平的垂体激素，不过溴隐亭能降低肢端肥大症病人已升高的生长激素(GH)水平。这些是由于它激动多巴胺受体所致。促乳素是产后泌乳开始及维持所必需的。但在哺乳期外，泌乳素的增加会引起病理性泌乳(乳溢)和(或)造成排卵紊乱、月经不调。对合并闭经及／或无排卵乳的乳溢病人，本品可使其排卵及月经周期正常化。使用溴隐亭不需限制液体的摄取。
溴隐亭不会影响产后子宫复原，也不增加血栓栓塞的危险。已证实本品能抑制或缩小促乳素瘤。
对肢端肥大症病人，本品除能降低血浆中GH和促乳素水平外，还能改善病人的临床症状和糖耐量。
滨隐亭可恢复黄体生成素的正常分泌，从而改善多囊卵巢综合征的临床症状。
对乳房良性疾病病人，溴隐亭可减少乳房囊肿及(或)小结的数量和体积。减轻孕激素／雌激素不平衡所致的乳房疼痛。同时可降低原已升高的促乳素水平。
〔药代动力学〕
溴隐亭口服吸收快而好，在1～3h内达高峰血药浓度。吸收后1～2h内，即发挥降促乳素作用，在5h后达最大效应，并持续8～12h。药物主要在肝内代谢，原型药在血浆中以双相消除，半衰期约为15h，原型药和代谢物几乎全部经肝排泄，仅6%经肾排泄。药物与血浆蛋白的结合率为96%。迄今尚无证据显示，高龄对溴隐亭的药代动力学特性及耐受量有直接影响。但在肝功能受损病人中，其代谢速度会减慢，血药浓度可能增高，此时需调整剂量。
〔适应证〕
1．由促乳素引起的月经不调及女性不孕症(促乳素过高或正常情况下) 闭经(乳溢或无乳溢)；黄体期过短；药物引起的高促乳素血症(如某此精神治疗或抗高血压药)与促乳素无关的女性不孕症。多囊卵巢综合征：无排卵周期(与抗雌激素药合用，如氯米芬)。月经前症状。乳房触痛，周期性水肿，浮肿，情绪障碍。男性的高促乳素血症。与促乳素有关的性功能低下(少精，性欲减退，阳痿)。
2．促乳素瘤 促乳素引起的垂体前叶微小或巨大腺瘤的保守治疗；手术前服用，为减小肿瘤体积以利手术切除；手术后促乳素水平仍过高者。
3．肢端肥大症 为辅助治疗，或在某些特殊情况下，作为手术或放射治疗的替代疗法。
4．良性乳腺疾病 乳房疼痛(与经前综合征或良性结节或囊肿有关或无关)；良性囊肿和(或)结节，特别是纤维囊性乳房疾病。
〔剂量和用法〕
溴隐亭应在用餐中服用。
1．促乳素引起的月经不调，女性不孕症 半片／次，每日2～3次，如果效果不显着，可逐渐增至1片／次，每天2～3次，持续治疗至月经周期恢复正常以及(或)恢复排卵。如有需要，可继续治疗几个月经周期以防其复发。
2．月经前症状 月经周期第14天开始每天用半片，然后每天增加半片直至1片／次，每天2次为止，并连续服用至月经来潮。
3．男性性功能低下 半片／次，每天2～3次，逐渐增加至2～4片／d。
4．促乳素瘤 半片／次，每天2～3次，逐渐增加至每天1至数片，以保证血浆中促乳素水平得到良好控制。
5．肢端肥大症 从半片／次，每天2～3次开始，根据临床反应和副作用，逐渐增加至4～8片／d。
6．产后乳房过度充胀 服用1片即可，如有需要可于6～12h后再服用一片。此剂量不会抑制泌乳。
7．产后初期乳腺炎 1片／次，每天2次，在早晚餐时服，共14d，必要时与抗生素合用。
8．良性乳房疾病。
〔禁忌证〕
对溴隐亭或其它麦角碱过敏者禁用。妊娠妇女的使用请参照“使用于孕妇”一栏。
〔注意事项〕
溴隐亭治疗可能会恢复生育能力，不愿生育的育龄妇女，服用溴隐亭期间须使用可靠的避孕措施。
非高促乳素血症的妇女使用溴隐亭治疗时，应从最低有效剂量开始，以避免造成促乳素低于正常水平而对黄体造成损害。乳房疼痛或乳房有囊肿、小结的病人在使用本品前，应作适当检查，以排除恶性病变的可能。偶有报告肢端肥大症病人，单用溴隐亭或合用其它药物引起肠胃出血，故在有更多的资料参考使用前，有消化道溃疡病史的肢端肥大症病人最好先使用其它方法治疗。若这些病人必须使用溴隐亭，则于使用期间，只要有任何肠胃道反应，应迅速报告医师。有精神障碍或严重心血管病史者，须小心使用溴隐亭。溴隐亭在肝功不全时消除更慢。有些病人使用溴隐亭的头几天会有低血压困扰，因此驾驶及操作机械宜小心。酒精可降低病人对溴隐亭的耐受性。与所有药物一样，溴隐亭应置于孩童接触不到的地方。
〔使用于孕妇〕
欲怀孕的病人，一旦证实怀孕时，除非医疗原因需要继续治疗外，溴隐亭与其它药物一样，应停止使用。在此情况下停用溴隐亭并不会增加流产率，大量经验显示妊娠期服用溴隐亭对妊娠过程及分娩无不良影响，垂体腺瘤病人怀孕时，应停用溴隐亭，并在妊娠期间作严密的观察。促乳素瘤有明显增大的症状时，如头痛或视野缺损，恢复溴隐亭的治疗或行外科手术可能是适当的。
〔相互作用〕
与红霉素或交沙霉素合用可提高溴隐亭的血药浓度。
〔副作用〕
治疗的最初几天，某些病人可能有轻微的恶心，极少数病人可能出现眩晕、疲乏或呕吐，但不致于严重到需要停药。若需要的话，可于服溴隐亭1h前使用抗呕吐药来防止初期的恶心、呕吐、头痛。极少数病人可能有低血压现象，因此，门诊病人在治疗的最初几天宜定期测量血压。体位性低血压亦可能发生，但可对症治疗。使用高剂量时可能有便秘、嗜睡，极少数病例偶呈精神紊乱、精神运动性兴奋、幻觉、运动不能、口干及下肢痉挛。这些副作用均与剂量有关，通常降低剂量即可控制。曾患雷诺病者，长期服用时由寒冷引起的可逆性手指、脚趾苍白亦曾被报道。
〔过量的处理〕
未见有服药过量引起致命性反应的报告，至今成人所服的单次最高剂量为225mg，所见到的症状有恶心、呕吐、眩晕、体位性低血压、出汗、嗜睡和幻觉。对急性中毒病人可采取对症处理，甲氧氯普胺(胃复安)可用于治疗呕吐和幻觉症状。
二、神经病学适应证
〔特点和作用〕
自发性和脑炎后帕金森病，可单独使用或合并其它抗帕金森病药。
由于溴隐亭具有多巴胺能的活性，在使用比治疗内分泌适应证较高剂量时，能有效地治疗因黑质纹状体多巴胺缺乏引起的帕金森病。溴隐亭可激动多巴胺受体，使纹状体内的神经化学恢复平衡。临床上，溴隐亭改善震颤，僵直，活动迟缓和帕金森病任何阶段的其它症状。通常疗效可保持多年(迄今，有病人保持良好效果达8年之久)。溴隐亭既可单独使用，也可在早期和晚期合并其它的抗帕金森病药。与左旋多巴合用可加强抗帕金森病的作用，同时可减少左旋多巴的用量。对长期使用左旋多巴发生疗效减退或产生不随意的异常运动〔如舞蹈病样运动障碍和(或)疼痛性张力障碍〕，用药末期失效和“开关”现象的病人，溴隐亭可提供特别有效的治疗。
溴隐亭可改善帕金森病病人常有的抑郁症，这是由于溴隐亭的内在抗抑郁作用。这一作用在有内源性或精神性抑郁症的非帕金森病病人的控制试验中得到证实。
〔药代动力学〕
请参阅“内分沁学适应证”有关说明。
〔剂量和用法〕
溴隐亭应在用餐中服用。
为了得到最佳耐受量，治疗应从低剂量开始，第一周1．25mg／d(半片)于晚上服用。为了取得每个病人的最小有效量，应根据病人的治疗反应逐渐调整剂量，即每周增加1．25mg／d，每天用量分2～3次服用。本品可在6～8周内产生最充分的治疗反应。否则，每周应增加2．5mg／d。在剂量调整阶段，一旦发生不良反应，应减少其每天用量，并维持该剂量至少1周。假如不良反应消失，则可以再次逐渐加量，对于使用左旋多巴治疗而出现运动障碍的病人，建议改用溴隐亭，并在使用前减少左旋多巴的用量。当获得满意疗效时，则可逐步减少左旋多巴的量。在某些病人中，左旋多巴甚至可以完全停掉。
溴隐亭于单独或合并使用时，其剂量通常为10～40mg／d，某些病人可能需要更高剂量。
〔禁忌证〕
尚无绝对禁忌，妊娠妇女的使用请参照“使用于孕妇”一栏。
〔注意事项〕
曾患精神病、严重心血管病、胃溃疡或肠胃出血的病人应小心使用高剂量的溴隐亭。
长期服用高剂量溴隐亭的帕金森病病人曾有胸膜液渗出的报告。若病人出现无法解释的胸膜与肺部症状时应详加检查，并考虑停药。
少数病人多年服用溴隐亭，其用量高于30mg／d，可能会有腹膜后纤维化现象。为了早期发现腹膜后纤维化，须注意在可逆阶段所产生的症状(例如：背痛、下肢水肿、肾功能损害)。若确诊或怀疑有腹膜后纤维变性。应停止使用溴隐亭。
其余注意事项请参照“内分泌学适应证”有关说明。
〔相互作用〕
请参照“内分泌学适应证”有关说明。
〔副作用〕
请参照“内分泌学适应证”有关说明。
〔包装〕
片剂：30片，100片，瓶装。
〔其它资料〕
药品于失效期(印在包装盒上)后，不得使用。本品应避光并贮存于25℃以下。
〔生产厂家〕
瑞士巴塞尔山道士制药公司
(附本品别名：麦角溴胺，溴麦角隐亭，溴麦角环肽，抑乳停，Bromergon，cB-154，Eygolactin，Pyavidel)
【外文释文】：
Dopamine-receptor stimulant，inhibitor of prolactin secretion
Composition
Active ingredient
Bromocriptine，as the mesylate
Tablets(scored) 2．5 mg
Capsules 5 or 10 mg
INN rec．for 2-bromo-α-ergocryptine
Parlodel is used in two different types of indication．
A Endocrinological indications
B Neurological indications
A Endocrinological indications
Properties／Actions
Parlodel inhibits secretion of the anterior pituitary hormone prolactin without affecting normal levels of other pituitary hormones，although it does reduce elevated levels of growth hormone(GH)in patients with acromegaly．These effects are due to stimulation of dopamine receptors．
Following childbirth prolactin is necessary for the initiation and maintenance of lactaticn，but at other times increased prolactin secretion gives risk to pathological lactation(galactorrhoea)and／or disorders of ovulation and menstruation．
As a specific inhibitor of prolactin secretion Parlodel can be used to prevent or suppress physiological lactation as well as to treat prolactin-induced pathological lactation as well as to treat prolactin-induced pathological states，with normalization of the menstrual cycle and ovu1ation in patients with amenorrhoea and／or anovulation(with or without galactorrhoea)．
The customary measures taken during lactation suppression，such as the restriction of fluid intake，are not necessary with Parlodel．In addition，Parlodel does not impair puerperal involution of the uterus or increase the risk of thromboembolism．
Parlodel has also been shown to arrest the growth or reduce the size of prolactin-secreting pituitary adenomas(prolactinomas)．
In acromegalic patients Parlodel has a beneficial effect on clinical symptoms and glucose tolerance，as well as lowering plasma GH and prolactin．
Parlodel induces a normal pattern of LH secretion，thereby improving the clinical symptomatology in polycystic ovary syndrome．
By normalizing the underlying progesterone／oestrogen imbalance Parlodel reduces the size and number of cysts and／or nodules in patients with benign breast disease and alleviates the associated pain．It also reduces prolactin secretion in patients with elevated blood levels．
Pharmacokinetics
Absorption of orally administered Parlodel(bromocriptine)is rapid and good，and peak plasma levels are attained within 1-3 hours．Its prolactin-lowering action begins to take effect l-2 hours after ingestion，peaks after approx．5 hours and is maintaind for 8-12 hours．Metabolism is predominantly hepatic．Elimination is bi-phasic，with a terminal half-life of approx．15 hours．Both parent drug and metabolites are excreted almost entirely via the liver，renal excretion accounting for only 6%．Protein binding is 96%．
There is no evidence that the pharmacokinetic properties or tolerability of Parlodel are altered in elderly patients．However，in patients with impaired liver function，slower elimina tion may give rise to higher plasma levels，making dose adjustment necessary．
Indications／Uses
Prolactin-induced menstrual disorders and female infertility(i．e．hyperprolactinaemic and apparently normoprolactinaemic conditions)
·Amenorrhoea(with or without galactorrhoea)
·Oligomenorrhoea
·Luteal-phase deficiency
·Drug-induced hyperprolactinaemic disorders(e．g．due to certain psychotropic or antihypertensive agents)
Prolactin-independent female infertility
·Polycystic ovary syndrome
·Anovulatory cycles(to supplement anti-oestrogens，e．g．clomifene)
Premenstrual symptoms
·Breast tenderness，cyclic oedema，abdominal bloating，mood disturbances
Hyperprolactinaemia in males
·Prolactin-induced hypogonadism(oligospermia，loss of libido，impotence)
Prolactinomas
·Conservative treatment of pituitary micro-or macroprolactinomas
·Presurgical reduction of tumour size to facilitate resection
·Postsurgical inhibition of persistent hyperprolactinaemia
Acromegaly
·As an adjunct to other therapy
·As an alternative to surgery or radiotherapy in special cases
Inhibition of lactation
·Prevention or suppression of puerperal lactation for medical reasons
·Prevention of lactation following abortion
·Puerperal breast engorgement
·Incipient puerperal mastitis
Benign breast disease
·Mastalgia(isolated or in association with premenstrual syndrome or with’benign nodular or cystic changes)
·Benign cystic and／or nodular conditions，in particular fibrocystic breast disease
Dosage／administration
Parlodel should always be taken with food．
Menstrual-cycle disorders，Female infertility
1．25 mg(1／2 tablet)two or three times daily，if this proves inadequate，gradually in crease to 2．5 mg(one tablet)two or three times daily．Treatment should be continued until the menstrual cycle is normalized and／or ovulation occurs and，if necessary，over several cycles to prevent relapse．
Premenstrual symptoms
1．25 mg(1／2 tablet)Daily starting on day 14 of the cycle and increasing in steps of 1．25 mg daily up to 2．5 mg(one tablet)twice daily until menstruation begins．
Male hypogonadism
1．25 mg(1／2 tablet)Two or three times daily，gradually increasing to 5-10 mg(2-4 tablets)daily．
Prolactinoma
1．25 mg(1／2 tablet)Two or three times daily，gradually increasing to several tablets daily as required for control or plasma prolactin．
Acromegaly
1．25 mg(1／2 tablet)Two or three times daily，gradually increasing ot 10-20 mg(4-8 tablets)daily depending on clinical response and adverse reactions．
Inhibition of lactation
2．5 mg(one tablet)Twice daily with morning and evening meals for 14 days．To prevent the onset of lactation treatment should be instituted within a few hours after parturition or abortion，but not before vital signs have stabilized．Slight milk secretion occasionally occurs 2-3 days after treatment has been withdrawn．This can be stopped by resuming treatment at the same dosage for a further week．
Puerperal breast engorgement
Single dose of 2．5 mg(one tablet)；may be repeated after 6-12 hours without causinginappropriate suppression of lactation．
Incipient puerperal mastitis
Same dosage as for inhibition of lactation．An antibiotic may be added to the regimen as required．
Benign breast disease
Ideally Parlodel should be taken over the whole of the menstrual cycle，starting at 1．25 mg(1／2 tablet)two or three times daily and building up gradually to the full dose of 5-7．5 mg(2-3 tablets)daily．Treatment should normally be discontinued if this dosage brings no satisfactory improvement within 3 months．
Restrictions on Use
Contraindications
Hypersensitivity to bromocriptine or other ergot alkaloids．
Hypertensive states of pregnancy，the post partum of puerperium．
For procedure during pregnancy see “Pregnancy／Lactation”．
Precautions
In rare cases(about 1 in 100000 post-partum women treated with Parlodel for the prevention of lactation)serious adverse events，including hypertension，myocardial infarction，seizuresst roke and psychotic disorders，have been reported．In some patients seizure or stroke was preceded by severe headache and／or transient visual disturbances．Although a causal connection is doubtful，the possibility cannot be excluded that Parlodel might be associated with an increased risk of cerebro-and cardiovascular complications in a small number of women following childbirth．Women with high blood pressure，coronary artery disease or evidence and／or a history of serious psychotic disorders should therefore not be given the drug post partum or during the puerperium．Blood pressure should be carefully monitored in postpartum women，especially during the first few days of therapy．Particular caution is required in patients recently treated or currently receiving drugs that can alter blood pressure，Although there is no conclusive evidence of an interaction between Parlodel and other ergot alkaloids(e．g．ergometrine，methylergometrine)，concomitant use is not recommeded．Treatment should be discontinued immediately if hypertension or any sign of CNS toxicity(such as persistent headache)develops．
Infertility may be reversed by treatment with Parlodel and women of child-bearing age who do not wish to become pregnant should be advised to use a reliable method of contraception．
Non-hyperprolactinaemic women should be given Parlodel in the lowest dose necessary to achieve relief of symptoms in order to avoid the possibility of hypoprolactinaemia，with the risk of luteal function impairment．
In patients to be treated for mastalgia or nodular and／or cystic breast changes，malignancy must first be excluded by appropriate diagnostic procedures．
There have been occasional reports of gastrointestinal bleeding in acromegalic patients being treated with Parlodel but also in patients receiving other，or even no，medication．Until further data are available，therefore，patients with peptic ulcer or a history of peptic ulcer should be given alternative treatment．If such patients have to be given Parlodel，they should be instructed to report any gastrointestinal reactions immediately．
Caution is required when giving Parlodel to patients with a history of psychotic disorders or severe cardiovascular disease．Bromocriptine may be eliminated more slowly in the presence of hepatic insufficiency．
Patients may experience hypotensive reactions during the first few days of treatment as a result of a fall in blood pressure and should therefore exercise particular care when driving vehicles or operating machinery．
The tolerability of Parlodel may be reduced by alcohol．Like all drugs，Parlodel should be kept out of reach of children．
Pregnancy／Lactation
Women wishing to have a child should be told to stop taking Parlodel and all other drugs as soon as pregnancy is confirmed，unless there is a medical reason for continuing to take it．No increased incidence of abortion has been reported following withdrawal of Parlodel and there is extensive evidence that it does not adversely affect the course or outcome of pregnancy．
Women with a pituitary adenoma who become pregnant and discontinue Parlodel must be closely monitored throughout the pregnancy and treatment resumed，or surgery considered，if evidence of，pronounced tumour enlargement(e．g．headache or visual field deterioration)is found．
Adverse Reactions
During the first few days of treatment some patients may experience slight nausea and，more rarely，dizziness，fatigue or vomiting，although these reactions are not usually severe enough to require discontinuation of treatment．If necessary，initial nausea and／or vomiting may be prevented by prescribing an anti-emetic to be taken one hour before ingestion of Parlodel．
Very occasionally Parlodel may induce orthostatic hypotension and ambulant patients，blood pressures should be checked during the first few days of treatment．This reaction may be troublesome but usually responds to symptomatic treatment．
The following adverse reactions have also been reported with high-dose Parlodel therapy：constipation，drowsinses，head-ache and，less frequently，confusion，psychomotor excitation，hallucinations，dyskinesia，dry mouth，leg cramps and allergic skin reactions．They are mostly dose-dependent and can usually be controlled by a reduction in dosage．
Episodes of reversible pallor of the fingers and toes induced by cold have occasionally been reported during prolonged treatment，particularly in patients with Raynaud’s phenomenon．
Bradycardia and transient disturbances of cardiac rhythm(bundle-branch block)have been reported with Parlodel．Retroperitoneal and pleural fibrosis has been documented in a few patients receiving oral doses of 30 mg or more daily over long periods(years)．
Interactions
Concomitant administration of erythromycin or josamycin may increase plasma brornocriptine levels．
Overdosage
No life-threatening reactions have been reported following acute overdosage．After 225 mg，the highest single dose so far ingested by an adult，the symptoms observed were nau sea，vomiting，dizziness，orthostatic hypotension，sweating，drowsiness and hallucinations．
Management of acute intoxication is symptomatic．Metoclopramide may be given to control vomiting and hallucinations．
B Neurological Indications
Properties／Actions
As a dopaminergic compound，Parlodel is effective in the treatment of Parkinson’s disease，although normally in higher doses than those given for its endocrinological indications．By stimulating the dopamine receptors，it reverses the specific nigrostriataldopamine deficiency that characterizes this condition．
Clinically，Parlodel improves tremor，rigidity，bradykinesia and other manifestations of the disease in all stages．Its therapeutic effect is normally maintained over long periods(up to 8 years among cases so far reported)．Parlodel can be given alone in both early-and advancedstage disease，or in combination with other antiparkinsonian drugs．Combination with levodopa results in an enhanced effect and enables the levodopa dose to be reduced in many cases．This is of particular benefit in levodopa patients experiencing deteriorating response or complications such as abnormal involuntary movements(choreo-athetoid dyskinesia and／or painful dystonia)，end-of-dose failure or‘on-off’phenomenon．Parlodel improves the depressive symptomatology often observed in parkinsonian patients．This is due to its specific antidepressant properties as substantiated by controlled studies in non-parkinsonian patients with endogenous or psychogenic depression．
Pharmacokinetics
See corresponding section under‘Endocrinological Indications’
Indications／Uses
All stages of idiopathic and postencephalitic Parkinson’s disease，either alone or in combination with other antiparkinsonian drugs．
Dosage／Administration
Parlodel should always be taken with food．
In order to ensure optimal tolerability，treatment should be started at 1．25 mg(1／2tablet)daily，preferably administered in the evening during the first week．The daily dosage should then be increased by 1．25 mg at weekly intervals until the lowest effective dose is established，it should always be given in 2 or 3 divided doses．If a satisfactory therapeutic response is not achieved within 6-8 weeks，further dose increases of 2．5 mg／day at weekly intervals may be attempted．
If adverse reactions occur during the dose-finding phase the daily dose should be reduced temporarily for at least one week．It may be increased again as soon as the adverse reactions disappear．
In patients exhibiting levodopa-induced motor disturbances，dosage should be reduced before introducing Parlodel．
Further gradual reduction may be possible once a satisfactory response to Parlodel has been obtained with the possibility of completed withdrawal in some cases．
The normal therapeutic range for Parlodel is 10-40 mg／day，whether it is being given alone or in combination with other agents，although some patients require higher doses．
Restrictions on Use
Contraindications
See corresponding section under“Endocrinological Indications”．
Precautions
Caution is required when giving Parlodel to patients with a history of psychotic disorders，severe cardiovascular disease，peptic ulcer or gastrointestinal bleeding．
Pleural effusions have occasionally been reported in parkinsonian patients receiving longterm，high-dose Parlodel therapy and unexplained pleuropulmonary changes should be thoroughly investigated and Parlodel discontinued if necessary．
Retroperitoneal fibrosis has been reported in a few patients treated over years with daily doses of Parlodel exceeding 30 mg．Careful observation is therefore recommended in order to ensure detection of its manifestations(e．g．back pain，peripheraloedema，impaired kidney function)in the early，reversible stage．Parlodel should be withdrawn if retroperitoneal fibrotic changes are diagnosed or suspected．For further precautions see corresponding section under“Endocrinological Indications”．
Adverse Reactions
See corresponding section under“Endocrinological Indications”and“Precautions”under“Neurological Indications”．
Interactions
See corresponding section under“Endocrinological Indications”．
Overdosage
See corresponding section under“Endocrinological Indications”．
Other Information
The drug should not be used after the expiry date(=EXP)printed on the pack．
Parlodel tablets should be stored at a temperature below 25℃and protected from light．
Manufacturer
Sandoz Pharma，Ltd．，Basle，Switzerland